Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $17.00 | Overweight | Cantor Fitzgerald |
| 5/10/2024 | $8.00 | Outperform | Leerink Partners |
| 4/11/2024 | $10.00 | Overweight | Piper Sandler |
| 3/28/2024 | $7.00 | Outperform | Raymond James |
Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
10-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the Piper Sandler Spring Biopharma Symposium in Boston. The Aquestive team will host investor meetings at the event on April 17. About Aquestive Therapeutics, Inc.Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administere
Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm™ Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance expected in Q2 2025 WARREN, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced positive topline results from its pediatric study for Anaphylm™ (epinephrine) sublingual film in patients aged seven to seventeen and weighing greater that thirty kilograms with a personal
Initiated Anaphylm™ (epinephrine) Sublingual Film NDA filing process with FDAAnaphylm pre-commercial activities underway; launch expected in Q1 2026, if approved by the FDAInitial Anaphylm pediatric clinical trial results in subjects 7-17 years of age in line with expectationsAQST-108 (epinephrine) Topical Gel Phase 2a clinical trial on track to begin in Q2 2025Proforma cash and cash equivalents as of December 31, 2024 approximately $93.0 millionCompany to host investment community conference call on March 6, 2025 WARREN, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medi
Cantor Fitzgerald initiated coverage of Aquestive Therapeutics with a rating of Overweight and set a new price target of $17.00
Leerink Partners initiated coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $8.00
Piper Sandler initiated coverage of Aquestive Therapeutics with a rating of Overweight and set a new price target of $10.00
SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)
SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)
SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)
Initiated Anaphylm™ (epinephrine) Sublingual Film NDA filing process with FDAAnaphylm pre-commercial activities underway; launch expected in Q1 2026, if approved by the FDAInitial Anaphylm pediatric clinical trial results in subjects 7-17 years of age in line with expectationsAQST-108 (epinephrine) Topical Gel Phase 2a clinical trial on track to begin in Q2 2025Proforma cash and cash equivalents as of December 31, 2024 approximately $93.0 millionCompany to host investment community conference call on March 6, 2025 WARREN, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medi
WARREN, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2024 and provide an update on recent developments in its business after market close on Wednesday, March 5, 2025. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, March 6, 2025. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A
Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024Libervant® (diazepam) Buccal Film for patients aged 2-5 available through retail distribution channelsFinished third quarter 2024 with approximately $78 million of cash and reaffirms cash runway into 2026To host investment community conference call at 8:00 am ET on November 5, 2024 WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative sci
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024. "We are honored that Aquestive is joining the Russell 3000 Index, which represents the 3,000 largest U.S. public
WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p
Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of ageAppointed Carl N. Kraus, M.D. as Chief Medical Officer WARREN, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and announced the appointment of Carl N. Kraus, M.D. as Chief Medical Officer of the Company. NDA Filing for Libervant for Pediatric PopulationAquestive submitted a N